In this video, developed in association with the European Breast Cancer Conference, Breast Cancer TV and Quadia Online Video and sponsored by an educational grant from Novartis Oncology: 
- Professor John Bartlett, PhD discusses the outcomes and findings of a debate on antracycline use and the search for a biomarker for antracycline sensitivity (Today?s practice changing presentation);
- Thomas Bachelot: MD, PhD, D?partement de Canc?rologie M?dicale et Unit? INSERM U590, Centre L?on B?rard, Lyon, France, highlights the clinical symposium on the management of mTOR inhibitor everolimus (Afinitor?, Novartis, Basel, Switzerland);
- David Cameron MD, Clinical Director and Chair of Oncology of the Edinburgh Cancer Research Center and Professor at the University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh, Scotland, comments on the survival data of BOLERO-2 (investigation the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer) and a novel approach with a HSP-90 inhibitor (Tomorrow?s practice changing presentation)
Copyright ? 2014 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
